Designing proteins that can bind to small molecules effectively
De novo design of small-molecule-binding proteins
This study is all about creating special proteins that can grab onto small medicines, like the blood thinner apixaban, more effectively, which could help improve treatments for people who need them.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Dana-Farber Cancer Inst NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project ID | NIH-10895518 on NIH RePORTER |
What this research studies
This research focuses on creating proteins that can bind to small molecules with high affinity and selectivity using advanced computational methods. By analyzing a large database of protein structures, the researchers aim to identify and utilize various molecular interaction motifs to design binding sites on proteins. This approach, known as Convergent Motifs for Binding Sites (COMBS), allows for the direct design of proteins without the need for random experimental optimization. One notable outcome of this research is the development of ABLER, a protein designed to bind the antithrombotic drug apixaban, which could have significant clinical applications.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals who may benefit from new anticoagulant therapies or those requiring targeted drug interventions.
Not a fit: Patients who do not require anticoagulant treatments or have conditions unrelated to small molecule interactions may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to the development of new therapeutic proteins that effectively target specific small molecules, improving treatment options for various conditions.
How similar studies have performed: Previous research has shown success in designing proteins with specific binding capabilities, indicating that this approach has potential for significant advancements.
Where this research is happening
Boston, United States
- Dana-Farber Cancer Inst — Boston, United States (Active)
Researchers
- Principal investigator: Polizzi, Nicholas — Dana-Farber Cancer Inst
- Study coordinator: Polizzi, Nicholas
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.